

Special Issue

Inflammation in Neurodegenerative Diseases: Mechanisms and Therapeutic Frontiers

Message from the Guest Editor

Chronic inflammation plays a critical role in the development and progression of many neurodegenerative diseases, including Alzheimer's, Parkinson's, multiple sclerosis, and age-related macular degeneration. Increasing evidence points to the complex involvement of immune responses, both in the brain and from the periphery, including the actions of microglia, astrocytes, and other immune cells, in driving neuronal damage and loss. This Special Issue, entitled *"Inflammation in Neurodegenerative Diseases: Mechanisms and Therapeutic Frontiers"*, invites contributions that explore how inflammation shapes the course of neurodegenerative diseases and what we can do to intervene. We are particularly interested in studies that uncover new mechanisms of neuroinflammation, identify promising biomarkers, and propose innovative therapies—ranging from gene therapy and immunomodulation to nanomedicine.

Guest Editor

Dr. Shao-Bin Wang

Department of Ophthalmology, University of Virginia School of Medicine, Charlottesville, VA 22903, USA

Deadline for manuscript submissions

1 January 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/241760

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).